289 related articles for article (PubMed ID: 17455190)
1. Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins.
Tietze LF; Major F; Schuberth I; Spiegl DA; Krewer B; Maksimenka K; Bringmann G; Magull J
Chemistry; 2007; 13(16):4396-409. PubMed ID: 17455190
[TBL] [Abstract][Full Text] [Related]
2. Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy.
Tietze LF; von Hof JM; Krewer B; Müller M; Major F; Schuster HJ; Schuberth I; Alves F
ChemMedChem; 2008 Dec; 3(12):1946-55. PubMed ID: 19021160
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy.
Tietze LF; Schuster HJ; Krewer B; Schuberth I
J Med Chem; 2009 Jan; 52(2):537-43. PubMed ID: 19143570
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of prodrugs based on the natural antibiotic duocarmycin for use in ADEPT and PMT.
Tietze LF; Schmuck K; Schuster HJ; Müller M; Schuberth I
Chemistry; 2011 Feb; 17(6):1922-9. PubMed ID: 21274943
[TBL] [Abstract][Full Text] [Related]
5. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
Tietze LF; Krewer B
Chem Biol Drug Des; 2009 Sep; 74(3):205-11. PubMed ID: 19660031
[TBL] [Abstract][Full Text] [Related]
6. Duocarmycin-based prodrugs for cancer prodrug monotherapy.
Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F
Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.
Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE
Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933
[TBL] [Abstract][Full Text] [Related]
8. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.
Tietze LF; Krewer B
Anticancer Agents Med Chem; 2009 Mar; 9(3):304-25. PubMed ID: 19275523
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.
Zhao RY; Erickson HK; Leece BA; Reid EE; Goldmacher VS; Lambert JM; Chari RV
J Med Chem; 2012 Jan; 55(2):766-82. PubMed ID: 22148292
[TBL] [Abstract][Full Text] [Related]
10. A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties.
Kupchinsky S; Centioni S; Howard T; Trzupek J; Roller S; Carnahan V; Townes H; Purnell B; Price C; Handl H; Summerville K; Johnson K; Toth J; Hudson S; Kiakos K; Hartley JA; Lee M
Bioorg Med Chem; 2004 Dec; 12(23):6221-36. PubMed ID: 15519165
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antitumor activity of CBI-bearing ester and carbamate prodrugs of CC-1065 analogue.
Wang Y; Li L; Tian Z; Jiang W; Larrick JW
Bioorg Med Chem; 2006 Dec; 14(23):7854-61. PubMed ID: 16908174
[TBL] [Abstract][Full Text] [Related]
12. The effect of a bromide leaving group on the properties of nitro analogs of the duocarmycins as hypoxia-activated prodrugs and phosphate pre-prodrugs for antitumor therapy.
Stevenson RJ; Denny WA; Ashoorzadeh A; Pruijn FB; van Leeuwen WF; Tercel M
Bioorg Med Chem; 2011 Oct; 19(20):5989-98. PubMed ID: 21920763
[TBL] [Abstract][Full Text] [Related]
13. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
14. Aldolase antibody activation of prodrugs of potent aldehyde-containing cytotoxics for selective chemotherapy.
Sinha SC; Li LS; Watanabe S; Kaltgrad E; Tanaka F; Rader C; Lerner RA; Barbas CF
Chemistry; 2004 Oct; 10(21):5467-72. PubMed ID: 15378729
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins.
Milbank JB; Stevenson RJ; Ware DC; Chang JY; Tercel M; Ahn GO; Wilson WR; Denny WA
J Med Chem; 2009 Nov; 52(21):6822-34. PubMed ID: 19821576
[TBL] [Abstract][Full Text] [Related]
17. Nitro seco analogues of the duocarmycins containing sulfonate leaving groups as hypoxia-activated prodrugs for cancer therapy.
Stevenson RJ; Denny WA; Tercel M; Pruijn FB; Ashoorzadeh A
J Med Chem; 2012 Mar; 55(6):2780-802. PubMed ID: 22339090
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of the first spacer containing prodrug of a duocarmycin analogue and determination of its biological activity.
Schuster HJ; Krewer B; von Hof JM; Schmuck K; Schuberth I; Alves F; Tietze LF
Org Biomol Chem; 2010 Apr; 8(8):1833-42. PubMed ID: 20449487
[TBL] [Abstract][Full Text] [Related]
19. A novel achiral seco-amino-cyclopropylindoline (CI) analog of CC-1065 and the duocarmycins: design, synthesis and biological studies.
Toth JL; Trzupek JD; Flores LV; Kiakos K; Hartley JA; Pennington WT; Lee M
Med Chem; 2005 Jan; 1(1):13-9. PubMed ID: 16789881
[TBL] [Abstract][Full Text] [Related]
20. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
Cai ZW; Zhang Y; Borzilleri RM; Qian L; Barbosa S; Wei D; Zheng X; Wu L; Fan J; Shi Z; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Kamath A; Marathe P; D'Arienzo C; Derbin G; Barrish JC; Robl JA; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2008 Mar; 51(6):1976-80. PubMed ID: 18288793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
